
Vaxcyte (PCVX) Stock Forecast & Price Target
Vaxcyte (PCVX) Analyst Ratings
Bulls say
Vaxcyte Inc. is positioned for a strong financial outlook, backed by a successful Phase 3 trial and favorable regulatory conditions that may lead to a re-rating in multiple expansion and heightened commercial success probabilities. The company's peak revenue estimate for 2040 has been adjusted upward to $6.8 billion, reflecting optimism regarding the adoption and market dynamics for its product candidate VAX-31, slated for launch in 2028. Additionally, positive recent clinical data, including superiority results in critical serotypes, enhances investor confidence and suggests a significant market opportunity, particularly with potential recommendations for broader adult usage of pneumococcal conjugate vaccines.
Bears say
Vaxcyte Inc. faces significant challenges that contribute to a negative outlook on its stock, particularly surrounding the anticipated results from its VAX-24 Phase 2 dose-finding trial, which underwhelmed investors amid elevated expectations for the infant pneumococcal conjugate vaccine market. Regulatory pressures and a more stringent vaccine approval environment have created additional headwinds, complicating the commercial viability of its product candidates, especially if national guidelines do not favor their use. Furthermore, the inherent risks of clinical trial outcomes, including potential safety and efficacy failures of its vaccine candidates, add further uncertainty to the company's financial prospects.
This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.
Vaxcyte (PCVX) Analyst Forecast & Price Prediction
Start investing in Vaxcyte (PCVX)
Order type
Buy in
Order amount
Est. shares
0 shares